TVAX Biomedical

TVAX Biomedical is a private, clinical-stage biotech focused on a novel, two-step personalized immunotherapy platform designed to treat a broad range of cancers with low toxicity. Its lead candidate, TVI-Brain-1, is in a pivotal Phase 2b trial for glioblastoma, supported by FDA Fast Track and Orphan Drug designations. The company leverages over 50 years of foundational research to create patient-specific therapies that aim to train the immune system to recognize and attack a patient's unique tumor antigens. Management combines deep scientific expertise in immunology with pharmaceutical development and operational experience.

Personalized, two-step autologous immunotherapy combining a patient-specific cancer cell vaccination with adoptive transfer of ex vivo activated killer T cells.

TVAX operates in the highly competitive immuno-oncology space, facing competition from large pharma and biotechs developing checkpoint inhibitors, CAR-T therapies (for other cancers), and other vaccine platforms. In glioblastoma specifically, it competes with standard of care and numerous investigational therapies, though its personalized, combined active/passive approach is a key differentiator.